Crucell N.V. is in preliminary discussions with Wyeth for the purchase of the Dutch vaccine company in a transaction valued at nearly $1.4 billion. In a statement, Crucell confirmed the talks, saying it is in “friendly discussions with Wyeth that may lead to a combination of the two companies.” The talks are at a “preliminary stage.” Crucell, which makes vaccines for hepatitis B, influenza, typhoid and cholera, would strengthen Wyeth’s efforts to accelerate revenue ...